Indian Clarity

Light. Truth. Clarity.

Loading ad...
Auto

Why Axsome Therapeutics Stock Rocketed Higher to End 2025

Why Axsome Therapeutics Stock Rocketed Higher to End 2025 Howard Smith, The Motley Fool Wed, December 31, 2025 at 11:02 PM GMT+5:30 3 min read AXSM Key Points Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD). Auvelity sales soared 69% in Q3.

Why Axsome Therapeutics Stock Rocketed Higher to End 2025

Credit: Yahoo

Key Highlights

  • 10 stocks we like better than Axsome Therapeutics › Axsome Therapeutics (NASDAQ: AXSM) shares soared to close out the year.
  • The company released two items of news today.
  • Investors see one in particular as a meaningful catalyst for the biopharmaceutical company that specializes in developing therapies for the management of depression and other neurological conditions.
  • Axsome shares rocketed more than 20% higher, and remained up by 19.4% as of 12:10 p. m.
  • ET.
Loading ad...

Sources

  1. Why Axsome Therapeutics Stock Rocketed Higher to End 2025

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

Related Stories

Loading ad...